Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7726016 | 0.94 | EDNRA (0.42) | EDNRATOP1SRD5A2LMNAL3MBTL1 | |
| SCHEMBL7726010 | 0.91 | TOP1 (0.41) | TOP1SRD5A2MAPK14FFAR1 | |
| SCHEMBL7735837 | 0.82 | LPAR1 (0.37) | PTGDR2 | |
| SCHEMBL7735835 | 0.80 | MTNR1A (0.43) | MAPK14MAOB | |
| SCHEMBL7735840 | 0.77 | LPAR1 (0.39) | — | |
| SCHEMBL7725867 | 0.75 | LPAR1 (0.42) | — | |
| SCHEMBL7734600 | 0.75 | ACAT1 (0.38) | — | |
| SCHEMBL7734475 | 0.74 | MAPT (0.39) | PTGDR2LMNAMAPK14 | |
| SCHEMBL7737859 | 0.74 | MEN1 (0.45) | GRM2 | |
| SCHEMBL7736090 | 0.74 | TLR4 (0.43) | MAPK14MAOBGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | EDNRA 4146/4885PTGDR2 3849/4885TOP1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.